Pharmacodynamics of Rituximab in Kidney Transplantation
The B-cell depleting anti-CD20 antibody rituximab has become a therapeutic alternative in renal transplantation. However, understanding of the pharmacodynamics is limited. We have therefore studied the effect of single-dose rituximab, in combination with conventional triple immunosuppressive therapy...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2007-12, Vol.84 (12), p.S33-S36 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S36 |
|---|---|
| container_issue | 12 |
| container_start_page | S33 |
| container_title | Transplantation |
| container_volume | 84 |
| creator | GENBERG, Helena HANSSON, Anneli WERNERSON, Annika WENNBERG, Lars TYDEN, Gunnar |
| description | The B-cell depleting anti-CD20 antibody rituximab has become a therapeutic alternative in renal transplantation. However, understanding of the pharmacodynamics is limited. We have therefore studied the effect of single-dose rituximab, in combination with conventional triple immunosuppressive therapy, on the B-cell population in peripheral blood as well as in tissues, in kidney transplant recipients. Forty-nine kidney recipients received single-dose rituximab. The prevalence of B cells was assessed in peripheral blood, kidney transplant tissue, and in lymph nodes. In 88%, complete depletion of B cells in peripheral blood was observed and, 15 months after treatment, B cells were still undetectable in the majority of patients. In kidney tissue, B cells were also completely eliminated. In contrast, the B cells were not eliminated in lymph nodes, although a reduction was observed. In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B-cells in peripheral blood as well as within the kidney transplant. |
| doi_str_mv | 10.1097/01.tp.0000296122.19026.0f |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_566598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20669740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-59899a1abc333cd858cbe5adda170631ed0481336c9c62c75d2ce3deeb3959383</originalsourceid><addsrcrecordid>eNqFkU1PwzAMhiMEYuPjL6BygFuLkyxpckQTX2ISCI1zlCapCKwfNK1g_56MVeOIL7asx_YrvwidY8gwyPwKcNa3GcQgkmNCMiyB8AzKPTTFjM5SDgL20RRghlNMaT5BRyG8R57RPD9EEywwJ1LwKcqf33RXadPYda0rb0LSlMmL74dvX-ki8XXy6G3t1smy03VoV7rude-b-gQdlHoV3OmYj9Hr7c1yfp8unu4e5teL1DCK-5RJIaXGujCUUmMFE6ZwTFurcQ6cYmdhJqJCbqThxOTMEuOoda6gkkkq6DFKt3vDl2uHQrVd1NWtVaO9GlsfsXKKcR6PRf5yy7dd8zm40KvKB-NWUbhrhqC4BAkg_gcJcC7zGURQbkHTNSF0rtxpwKA2dijAqm_Vnx3q1w4FZZw9G48MReXs3-T4_whcjIAORq_K-GTjw44jGwcjSH8AbJGT7w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20669740</pqid></control><display><type>article</type><title>Pharmacodynamics of Rituximab in Kidney Transplantation</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>GENBERG, Helena ; HANSSON, Anneli ; WERNERSON, Annika ; WENNBERG, Lars ; TYDEN, Gunnar</creator><creatorcontrib>GENBERG, Helena ; HANSSON, Anneli ; WERNERSON, Annika ; WENNBERG, Lars ; TYDEN, Gunnar</creatorcontrib><description>The B-cell depleting anti-CD20 antibody rituximab has become a therapeutic alternative in renal transplantation. However, understanding of the pharmacodynamics is limited. We have therefore studied the effect of single-dose rituximab, in combination with conventional triple immunosuppressive therapy, on the B-cell population in peripheral blood as well as in tissues, in kidney transplant recipients. Forty-nine kidney recipients received single-dose rituximab. The prevalence of B cells was assessed in peripheral blood, kidney transplant tissue, and in lymph nodes. In 88%, complete depletion of B cells in peripheral blood was observed and, 15 months after treatment, B cells were still undetectable in the majority of patients. In kidney tissue, B cells were also completely eliminated. In contrast, the B cells were not eliminated in lymph nodes, although a reduction was observed. In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B-cells in peripheral blood as well as within the kidney transplant.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/01.tp.0000296122.19026.0f</identifier><identifier>PMID: 18162986</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adult ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD19 - biosynthesis ; Antigens, CD20 - biosynthesis ; B-Lymphocytes - metabolism ; Biological and medical sciences ; Child ; Flow Cytometry - methods ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunohistochemistry - methods ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation - methods ; Lymph Nodes - pathology ; Medical sciences ; Models, Biological ; Rituximab ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue, organ and graft immunology ; Transplantation Immunology ; Treatment Outcome</subject><ispartof>Transplantation, 2007-12, Vol.84 (12), p.S33-S36</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-59899a1abc333cd858cbe5adda170631ed0481336c9c62c75d2ce3deeb3959383</citedby><cites>FETCH-LOGICAL-c531t-59899a1abc333cd858cbe5adda170631ed0481336c9c62c75d2ce3deeb3959383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,309,310,314,776,780,785,786,881,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20041298$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18162986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:116363642$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>GENBERG, Helena</creatorcontrib><creatorcontrib>HANSSON, Anneli</creatorcontrib><creatorcontrib>WERNERSON, Annika</creatorcontrib><creatorcontrib>WENNBERG, Lars</creatorcontrib><creatorcontrib>TYDEN, Gunnar</creatorcontrib><title>Pharmacodynamics of Rituximab in Kidney Transplantation</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>The B-cell depleting anti-CD20 antibody rituximab has become a therapeutic alternative in renal transplantation. However, understanding of the pharmacodynamics is limited. We have therefore studied the effect of single-dose rituximab, in combination with conventional triple immunosuppressive therapy, on the B-cell population in peripheral blood as well as in tissues, in kidney transplant recipients. Forty-nine kidney recipients received single-dose rituximab. The prevalence of B cells was assessed in peripheral blood, kidney transplant tissue, and in lymph nodes. In 88%, complete depletion of B cells in peripheral blood was observed and, 15 months after treatment, B cells were still undetectable in the majority of patients. In kidney tissue, B cells were also completely eliminated. In contrast, the B cells were not eliminated in lymph nodes, although a reduction was observed. In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B-cells in peripheral blood as well as within the kidney transplant.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD19 - biosynthesis</subject><subject>Antigens, CD20 - biosynthesis</subject><subject>B-Lymphocytes - metabolism</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Flow Cytometry - methods</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation - methods</subject><subject>Lymph Nodes - pathology</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Rituximab</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue, organ and graft immunology</subject><subject>Transplantation Immunology</subject><subject>Treatment Outcome</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1PwzAMhiMEYuPjL6BygFuLkyxpckQTX2ISCI1zlCapCKwfNK1g_56MVeOIL7asx_YrvwidY8gwyPwKcNa3GcQgkmNCMiyB8AzKPTTFjM5SDgL20RRghlNMaT5BRyG8R57RPD9EEywwJ1LwKcqf33RXadPYda0rb0LSlMmL74dvX-ki8XXy6G3t1smy03VoV7rude-b-gQdlHoV3OmYj9Hr7c1yfp8unu4e5teL1DCK-5RJIaXGujCUUmMFE6ZwTFurcQ6cYmdhJqJCbqThxOTMEuOoda6gkkkq6DFKt3vDl2uHQrVd1NWtVaO9GlsfsXKKcR6PRf5yy7dd8zm40KvKB-NWUbhrhqC4BAkg_gcJcC7zGURQbkHTNSF0rtxpwKA2dijAqm_Vnx3q1w4FZZw9G48MReXs3-T4_whcjIAORq_K-GTjw44jGwcjSH8AbJGT7w</recordid><startdate>20071227</startdate><enddate>20071227</enddate><creator>GENBERG, Helena</creator><creator>HANSSON, Anneli</creator><creator>WERNERSON, Annika</creator><creator>WENNBERG, Lars</creator><creator>TYDEN, Gunnar</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>ADTPV</scope><scope>BNKNJ</scope></search><sort><creationdate>20071227</creationdate><title>Pharmacodynamics of Rituximab in Kidney Transplantation</title><author>GENBERG, Helena ; HANSSON, Anneli ; WERNERSON, Annika ; WENNBERG, Lars ; TYDEN, Gunnar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-59899a1abc333cd858cbe5adda170631ed0481336c9c62c75d2ce3deeb3959383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD19 - biosynthesis</topic><topic>Antigens, CD20 - biosynthesis</topic><topic>B-Lymphocytes - metabolism</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Flow Cytometry - methods</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation - methods</topic><topic>Lymph Nodes - pathology</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Rituximab</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue, organ and graft immunology</topic><topic>Transplantation Immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GENBERG, Helena</creatorcontrib><creatorcontrib>HANSSON, Anneli</creatorcontrib><creatorcontrib>WERNERSON, Annika</creatorcontrib><creatorcontrib>WENNBERG, Lars</creatorcontrib><creatorcontrib>TYDEN, Gunnar</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Conference</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GENBERG, Helena</au><au>HANSSON, Anneli</au><au>WERNERSON, Annika</au><au>WENNBERG, Lars</au><au>TYDEN, Gunnar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacodynamics of Rituximab in Kidney Transplantation</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2007-12-27</date><risdate>2007</risdate><volume>84</volume><issue>12</issue><spage>S33</spage><epage>S36</epage><pages>S33-S36</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>The B-cell depleting anti-CD20 antibody rituximab has become a therapeutic alternative in renal transplantation. However, understanding of the pharmacodynamics is limited. We have therefore studied the effect of single-dose rituximab, in combination with conventional triple immunosuppressive therapy, on the B-cell population in peripheral blood as well as in tissues, in kidney transplant recipients. Forty-nine kidney recipients received single-dose rituximab. The prevalence of B cells was assessed in peripheral blood, kidney transplant tissue, and in lymph nodes. In 88%, complete depletion of B cells in peripheral blood was observed and, 15 months after treatment, B cells were still undetectable in the majority of patients. In kidney tissue, B cells were also completely eliminated. In contrast, the B cells were not eliminated in lymph nodes, although a reduction was observed. In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B-cells in peripheral blood as well as within the kidney transplant.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>18162986</pmid><doi>10.1097/01.tp.0000296122.19026.0f</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 2007-12, Vol.84 (12), p.S33-S36 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_566598 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antigens, CD19 - biosynthesis Antigens, CD20 - biosynthesis B-Lymphocytes - metabolism Biological and medical sciences Child Flow Cytometry - methods Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunohistochemistry - methods Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Kidney Transplantation - methods Lymph Nodes - pathology Medical sciences Models, Biological Rituximab Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Tissue, organ and graft immunology Transplantation Immunology Treatment Outcome |
| title | Pharmacodynamics of Rituximab in Kidney Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A56%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacodynamics%20of%20Rituximab%20in%20Kidney%20Transplantation&rft.jtitle=Transplantation&rft.au=GENBERG,%20Helena&rft.date=2007-12-27&rft.volume=84&rft.issue=12&rft.spage=S33&rft.epage=S36&rft.pages=S33-S36&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/01.tp.0000296122.19026.0f&rft_dat=%3Cproquest_swepu%3E20669740%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20669740&rft_id=info:pmid/18162986&rfr_iscdi=true |